Ranger Investment Management L.P. Lowers Stake in iRadimed Corporation $IRMD

Ranger Investment Management L.P. lessened its stake in iRadimed Corporation (NASDAQ:IRMD) by 44.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 119,620 shares of the medical equipment provider’s stock after selling 95,220 shares during the period. Ranger Investment Management L.P. owned 0.94% of iRadimed worth $8,512,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in IRMD. Summit Global Investments grew its stake in iRadimed by 2.7% in the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after acquiring an additional 188 shares in the last quarter. CWM LLC increased its holdings in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares during the period. Police & Firemen s Retirement System of New Jersey raised its position in iRadimed by 30.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,056 shares of the medical equipment provider’s stock valued at $123,000 after purchasing an additional 477 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Stock Performance

NASDAQ:IRMD opened at $95.60 on Friday. The stock has a market capitalization of $1.22 billion, a P/E ratio of 58.14 and a beta of 1.11. The company’s 50-day simple moving average is $97.69 and its 200-day simple moving average is $82.17. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $104.93.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. On average, research analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Dividend Announcement

The firm also recently declared a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were issued a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is currently 41.21%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Roth Mkm set a $90.00 price target on iRadimed in a research note on Friday, October 31st. Lake Street Capital reiterated a “buy” rating and set a $100.00 target price on shares of iRadimed in a report on Monday, November 3rd. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Finally, Zacks Research raised shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.00.

Insider Activity

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $100.65, for a total value of $503,250.00. Following the completion of the transaction, the chief executive officer owned 2,262,500 shares of the company’s stock, valued at approximately $227,720,625. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the sale, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 55,000 shares of company stock worth $5,287,900. Corporate insiders own 36.80% of the company’s stock.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.